Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice

Paul V Williams1,2

  • 1Department of Pediatrics, Allergy Division, University of Washington School of Medicine, Seattle, WA, USA. pwilliams@nwasthma.com.

Paediatric Drugs
|December 21, 2019
PubMed

Insights

Chronic urticaria in children, though uncommon, significantly impacts quality of life and healthcare costs. Current treatment guidelines are underutilized, leading to overuse of sedating antihistamines and oral steroids.

Area of Science:

  • Pediatric Allergy and Immunology
  • Dermatology
  • Clinical Immunology

Background:

  • Chronic urticaria (CU) is an uncommon pediatric disorder with significant morbidity and healthcare costs.
  • Chronic spontaneous urticaria (CSU) accounts for 70-80% of cases, with chronic autoimmune urticaria (CAU) being a significant subtype.
  • Chronic inducible urticaria (CIU) accounts for 15-20% of cases, triggered by external stimuli.

Purpose of the Study:

  • To review the prevalence, impact, and current guidelines for diagnosing and treating chronic urticaria in children.
  • To highlight the gap between recommended and real-world treatment practices.
  • To emphasize the need for better guideline adherence to reduce morbidity and costs.

Main Methods:

  • Review of existing literature and clinical guidelines for pediatric chronic urticaria.
  • Analysis of the impact of CU on quality of life and healthcare utilization.
  • Comparison of guideline-recommended treatments with real-world prescribing patterns.

Main Results:

  • CU negatively impacts children's quality of life, comparable to chronic diseases like diabetes.
  • Healthcare costs for CU patients are significantly higher due to increased hospitalizations and visits.
  • Real-world studies show overutilization of sedating antihistamines and oral steroids, contrary to guidelines.

Conclusions:

  • Adherence to established guidelines for CU diagnosis and treatment is crucial.
  • Optimizing treatment strategies, including appropriate antihistamine use, can reduce morbidity and healthcare burden.
  • Closing the gap between guidelines and practice is essential for improved pediatric chronic urticaria management.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
173
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
207
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
196
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
210
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
154
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
380